We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+10.97%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$5.05B
AUM Growth
+$206M
Cap. Flow
-$221M
Cap. Flow %
-4.38%
Top 10 Hldgs %
83.23%
Holding
98
New
29
Increased
15
Reduced
26
Closed
6

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$8.14M
2
AMAG
AMAG Pharmaceuticals
AMAG
+$7.5M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$6.05M
4
ATRA icon
Atara Biotherapeutics
ATRA
+$4.89M
5
NTB icon
Bank of N.T. Butterfield & Son
NTB
+$4.86M

Top Sells

Rank Stock Value
1
BUFF
Blue Buffalo Pet Products, Inc
BUFF
+$699M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$20.1M
3
C icon
Citigroup
C
+$10.6M
4
BABA icon
Alibaba
BABA
+$9.27M
5
APTV icon
Aptiv
APTV
+$8.43M

Sector Composition

Rank Sector Weight
1 Consumer Staples 41.33%
2 Healthcare 27.87%
3 Consumer Discretionary 7.22%
4 Financials 1.42%
5 Energy 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AEGR
76
DELISTED
Aegerion Pharmaceuticals
AEGR
$2.97M 0.06%
1,000,000
– –
NERV icon
77
Minerva Neurosciences
NERV
$191M
$2.82M 0.06%
+25,000
New +$2.43M
CMRX
78
DELISTED
Chimerix, Inc.
CMRX
$2.77M 0.05%
+500,000
New +$2.29M
CLDX icon
79
Celldex Therapeutics
CLDX
$2.94B
$2.73M 0.05%
45,000
– –
RDUS
80
DELISTED
Radius Health, Inc.
RDUS
$2.71M 0.05%
50,000
-50,000
-50% -$2.54M
ACIU icon
81
AC Immune
ACIU
$231M
$2.47M 0.05%
+150,000
New +$2.59M
GBT
82
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.31M 0.05%
100,000
-25,000
-20% -$476K
CLCD
83
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$2.12M 0.04%
55,575
+50,000
+897% +$739K
LOXO
84
DELISTED
Loxo Oncology, Inc
LOXO
$1.96M 0.04%
+75,000
New +$1.96M
DMTX
85
DELISTED
Dimension Therapeutics, Inc
DMTX
$1.87M 0.04%
234,493
-40,507
-15% -$293K
DO
86
DELISTED
Diamond Offshore Drilling
DO
$1.76M 0.03%
+100,000
New +$2M
IBRX icon
87
ImmunityBio
IBRX
$7.15B
$1.75M 0.03%
225,000
– –
ADAP
88
DELISTED
Adaptimmune Therapeutics
ADAP
$1.41M 0.03%
+200,000
New +$1.53M
ISEE
89
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.38M 0.03%
30,000
-20,000
-40% -$1.13M
KDNY
90
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.24M 0.02%
+20,000
New +$1.41M
NVAX icon
91
Novavax
NVAX
$1.21B
$1.04M 0.02%
+25,000
New +$3.23M
IMDX
92
Insight Molecular Diagnostics
IMDX
$141M
$323K 0.01%
3,205
– –
C icon
93
Citigroup
C
$213B
– –
-250,000
Closed -$10.6M
REGN icon
94
Regeneron Pharmaceuticals
REGN
$72.9B
– –
-50,000
Closed -$20.1M
SAGE
95
CALL
DELISTED
Sage Therapeutics
SAGE
– –
-100,000
Closed -$3.01M
VRTX icon
96
CALL
Vertex Pharmaceuticals
VRTX
$123B
– –
-150,000
Closed -$12.9M
RDUS
97
CALL
DELISTED
Radius Health, Inc.
RDUS
– –
-100,000
Closed -$3.67M
CERE
98
DELISTED
CERES, INC. COMMON STOCK NEW
CERE
– –
-1,024,020
Closed -$400K
1 2 3
4

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2016 Portfolio in Review

As of Q3 2016, Artal Group held 98 positions worth $5.05B, up 4.3% from $4.84B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Artal Group withdrew a net $221M in Q3 2016, closing 6 positions and reducing 26 holdings. Its most notable exit was Regeneron Pharmaceuticals, an estimated $20.1M position sold in full.

By sector, the portfolio is most concentrated in Consumer Staples at 41% of assets, down from 56% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Artal Group opened a new position in Sage Therapeutics worth $9.21M.

  • Artal Group's largest Q3 2016 buy was Sage Therapeutics: 200,000 shares worth $9.21M.
  • Artal Group added most to Amicus Therapeutics in Q3 2016, an estimated $4.39M increase.
  • Artal Group's biggest Q3 2016 reduction was Blue Buffalo Pet Products, Inc, cutting an estimated $699M.
  • Artal Group fully exited Regeneron Pharmaceuticals in Q3 2016, selling an estimated $20.1M.
  • Artal Group's ten largest holdings make up 83% of its $5.05B portfolio in Q3 2016.
  • Artal Group opened 29 new positions and closed 6 in Q3 2016.
  • Artal Group's portfolio value rose 4.3% quarter-over-quarter to $5.05B.

Based on Artal Group's 13F filing for Q3 2016, filed 14 Nov 2016.